Last updated

Vaccine description
Target SARS-CoV-2
Vaccine type Viral vector
Clinical data
Routes of
ATC code
  • None

BBV154 is an intranasal COVID-19 vaccine candidate developed by Bharat Biotech, [1] [2] American company Precision Virologics [3] [4] and the Washington University School of Medicine in St Louis, Missouri ,United States. [5] [6]


Clinical trials

Phase I trials

On recommendation by the Subject Expert Committee (SEC) under the Indian drug regulator, the company is going to conduct phase 1 clinical trials using 75 volunteers and submit safety and immunogenicity data for the committee’s consideration before it proceeds to the second phase of the trial. [7]

Phase II and III trials

On 12 August 2021, after evaluating the results of phase I trial data, the drug regulator approved for phase II/III randomized trials that involves evaluation of the immunogenicity and safety of Covaxin with BBV154 in healthy volunteers. [8]

Related Research Articles

Arcturus Therapeutics is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed a novel, potent, and safe RNA therapeutics platform called LUNAR, a proprietary lipid-enabled delivery system for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides (ASO), and microRNA.

Valneva SE is a French biotech company headquartered in Saint-Herblain, France, developing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden and Vienna, Austria, with other offices in France, Canada and the United States.

COVID-19 vaccine Vaccine designed to provide acquired immunity against SARS-CoV-2

A COVID‑19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19). Prior to the COVID‑19 pandemic, an established body of knowledge existed about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). This knowledge accelerated the development of various vaccine platforms during early 2020. The initial focus of SARS-CoV-2 vaccines was on preventing symptomatic, often severe illness. On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19. The COVID‑19 vaccines are widely credited for their role in reducing the spread, severity, and death caused by COVID-19.

Bharat Biotech Indian biotechnology company and vaccine manufacturer

Bharat Biotech International Limited (BBIL) is an Indian multinational biotechnology company headquartered in Hyderabad, engaged in the drug discovery, drug development, manufacture of vaccines, bio-therapeutics, pharmaceuticals and health care products.

Covaxin Vaccine against COVID-19

Covaxin is an inactivated virus-based COVID-19 vaccine developed by Bharat Biotech in collaboration with the Indian Council of Medical Research.

Valneva COVID-19 vaccine Vaccine candidate against COVID-19

Valneva COVID-19 vaccine, also known as the VLA2001 and VLA2101, is a COVID-19 vaccine candidate developed by French biotechnology company Valneva SE in collaboration with American company Dynavax Technologies.

ZF2001 Vaccine against COVID-19

ZF2001, trade-named ZIFIVAX or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.

CoVLP COVID-19 vaccine candidate produced in a plant

CoVLP is a COVID-19 vaccine candidate developed by Medicago and GlaxoSmithKline (GSK). It is a coronavirus virus-like particle vaccine grown in the Australian weed, Nicotiana benthamiana.

ZyCoV-D Vaccine candidate against COVID-19

ZyCoV-D is a DNA plasmid-based COVID-19 vaccine developed by Indian pharmaceutical company Cadila Healthcare, with support from the Biotechnology Industry Research Assistance Council. It is approved for emergency use in India.

SCB-2019 Vaccine candidate against COVID-19

SCB-2019 is a protein subunit COVID-19 vaccine candidate developed by Clover Biopharmaceuticals using an adjuvant from Dynavax technologies. Positive results of Phase I trials for the vaccine were published in The Lancet and the vaccine completed enrollment in its Phase II/III trials in July 2021, with efficacy results expected to be announced by Q3 2021. SCB-2019 is being funded by CEPI as part of COVAX and has received advanced purchase orders from GAVI for 400 million doses.

Nanocovax Vaccine candidate against COVID-19

Nanocovax is a Vietnamese COVID-19 vaccine candidate developed by Nanogen Pharmaceutical Biotechnology JSC. It is a subunit vaccine.

Walvax COVID-19 vaccine Vaccine candidate against COVID-19

ARCoV, also known as the Walvax COVID-19 vaccine, is an mRNA COVID-19 vaccine candidate developed by Walvax Biotechnology, Suzhou Abogen Biosciences, and the PLA Academy of Military Science. It is approved for Phase III trials in China, Mexico, Indonesia, and Nepal.

Corbevax Vaccine candidate against COVID-19 and infertility

Corbevax or BioE COVID-19, is a COVID-19 vaccine candidate developed by Indian biopharmacutical firm Biological E. Limited (BioE), the Baylor College of Medicine in Houston, United States, and American company Dynavax Technologies (DVAX). It is a protein subunit vaccine.

Zhongyianke Biotech–Liaoning Maokangyuan Biotech COVID-19 vaccine Vaccine candidate against COVID-19

Zhongyianke Biotech–Liaoning Maokangyuan Biotech COVID-19 vaccine is a COVID-19 vaccine candidate developed by Zhongyianke Biotech, Liaoning Maokangyuan Biotech, and Academy of Military Medical Sciences. The vaccine is based on recombinant coronavirus spike protein produced in chinese hamster ovary cells. A phase 3 trial of 3 doses of this vaccine for 14,600 participants was registered in early September 2021.

Razi Cov Pars Vaccine candidate against COVID-19

Razi Cov Pars is a COVID-19 vaccine candidate developed by the Iranian Razi Vaccine and Serum Research Institute.

COVI-VAC (U.S. COVID-19 vaccine) Vaccine candidate against COVID-19

COVI-VAC is a COVID-19 vaccine being developed by Codagenix, Inc. It is a live attenuated vaccine administered intranasally and requires a single dose. It is currently in Phase 1 clinical trials, involving 48 participants which runs from December 2020 to June 2021.

FAKHRAVAC Vaccine against COVID-19

FAKHRAVAC is a COVID-19 vaccine developed in Iran by the Organization of Defensive Innovation and Research, a subsidiary of Iran's Ministry of Defense. It's the third Iranian COVID-19 vaccine reaching clinical trials. It's currently in phase III. It has received emergency use authorization in Iran on 9 September 2021.

COVAX-19 Vaccine candidate against COVID-19

COVAX-19 is a recombinant protein-based COVID-19 vaccine candidate developed by South Australian based biotech company, Vaxine. It is under clinical trial in collaboration with the Iranian company CinnaGen.

ARCT-154 Vaccine candidate against COVID-19

ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.

COVID-19 vaccine clinical research

COVID-19 vaccine clinical research is the clinical research on COVID-19 vaccines, including their efficacy, effectiveness and safety. There are 22 vaccines authorized for use by national governments, with six vaccines being approved for emergency or full use by at least one WHO-recognised stringent regulatory authority; and five of them are in Phase IV. 204 vaccines under clinical trials that have not yet been authorized. There are also nine clinical trials on heterologous vaccination courses.


  1. Clinical trial number NCT04751682 for "Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19" at
  2. "Intranasal Vaccine For Covid-19". Bharat Biotech. Retrieved 5 March 2021.
  3. "St. Louis-based Precision Virologics and India's Biotech leader Bharat Biotech obtain rights to intranasal COVID-19 vaccine technology". Retrieved 29 August 2021.
  4. Hassan, AO; Kafai, NM; Dmitriev, IP; Fox, JM; Smith, BK; Harvey, IB; Chen, RE; Winkler, ES; Wessel, AW; Case, JB; Kashentseva, E; McCune, BT; Bailey, AL; Zhao, H; VanBlargan, LA; Dai, YN; Ma, M; Adams, LJ; Shrihari, S; Danis, JE; Gralinski, LE; Hou, YJ; Schäfer, A; Kim, AS; Keeler, SP; Weiskopf, D; Baric, RS; Holtzman, MJ; Fremont, DH; Curiel, DT; Diamond, MS (1 October 2020). "A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2". Cell. 183 (1): 169-184.e13. doi:10.1016/j.cell.2020.08.026. PMC   7437481 . PMID   32931734.
  5. "Bharat Biotech to make a billion doses of an intranasal adenovirus vaccine". The Indian Express. 23 September 2020. Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  6. "Bharat Biotech Partners With US University For Covid Intranasal Vaccine". Archived from the original on 3 May 2021. Retrieved 23 September 2020.
  7. Raghavan P (30 January 2021). "Explained: Understanding BBV154, Bharat Biotech's single-dose intranasal Covid-19 vaccine". The Indian Express.
  8. Gaurav, Kunal (13 August 2021). "First nasal vaccine developed by Bharat Biotech gets nod for Phase 2/3 trial". Hindustan Times.